Sarah Boyce, president and chief executive officer, and Art Levin, chief scientific officer at Avidity Biosciences, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Feb. 24th.
The conference will be held in a virtual format and will be made available on Avidity's website in the Investors section.
Founded in 2013, the company aims to develop what it calls its Antibody Oligonucleotide Conjugate [AOC] platform for combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies for targeting the genetic drivers of dystrophy diseases.
Headquartered in La Jolla, it employs 73 staffers. Boyce has been with the firm since October 2019 and was previously president and Board member of Akcea Therapeutics (AKCA) and has held several senior positions in other biopharma companies.